NEW YORK (GenomeWeb News) – The US Food and Drug Administration today said it has cleared Affymetrix’s CytoScan Dx Assay for marketing in the US.

The assay can detect chromosomal variations that may be responsible for developmental delay or intellectual disability in children. The test analyzes an entire genome at one time and detects large and small chromosomal changes, based on a blood sample, FDA said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: epigenetic changes linked with high-altitude pulmonary edema, transcriptome profiling of maize leaf development, and more.

Stanford University researchers are studying top athletes to uncover genes linked to performance.

The UW's Wylie Burke and Dartmouth's Gilbert Welch argue that whole-genome testing may do more harm than good, and a related poll.

In PLOS this week: phylogenetic study of hepatitis E viruses in Swedish moose, recombination sites in the honeybee genome, and more.